The Research Institute of Molecular Pathology (IMP) is a biomedical research center, which conducts curiosity-driven basic research in the molecular life sciences.
The IMP is located at the Vienna Biocenter (VBC) in Vienna, Austria. The institute employs around 250 people from 36 nations, of which approximately 200 are scientists. The working language at the IMP is English. The IMP was established in 1985 and is funded by the pharmaceutical company Boehringer Ingelheim and research grants.
Research at the IMP aims to elucidate mechanisms and principles that underlie complex biological processes. Six general themes emerge from the work of the IMP research groups:molecular and cellular biology;
structural biology and biochemistry;
gene expression and chromosome biology;
stem cell biology and development;
immunology and cancer;
The research in these fields is pursued by 15 independent research groups, headed by principle investigators. The groups focus on the following topics:Meinrad Busslinger: stem cell commitment in hematopoiesis
Tim Clausen: molecular mechanisms of protein quality control
Luisa Cochella: spatio-temporal specificity of miRNA function and its role in cell-type specification
Wulf Haubensak: circuit mechanics of emotional behavior
David Keays: neuronal migration and magnetoreception
Thomas Marlovits: molecular machines
Anna Obenauf: molecular mechanisms of metastasis and drug resistance
Andrea Pauli: functions of short translated open reading frames (ORFs) in the context of development
Rushad Pavri: molecular mechanisms of antibody diversification
Jan-Michael Peters: mitosis and chromosome biology
Alexander Stark: systems biology of regulatory motifs and networks – towards understanding gene expression from the DNA sequence
Elly Tanaka: molecular mechanisms of vertebrate regeneration
Alipasha Vaziri: dynamics of coupled biological systems: methods and phenomena
Manuel Zimmer: the neural basis of behavior
Johannes Zuber: finding and probing cancer drug targets using advanced RNAi technologies
The establishment of the IMP was a joint venture by Boehringer Ingelheim and Genentech and initiated in 1985. Under the directorship of Max Birnstiel, the first institute building was opened in 1988.
In 1992, three institutes of the faculties of science and medicine of the University of Vienna moved into a nearby building, today's Max F. Perutz Laboratories (MFPL). This created the basis for referring to the area as the "Vienna Biocenter" (VBC).
In 1993, Boehringer Ingelheim took over the IMP shares of Genentech. Following Max Birnstiel's retirement in 1997, Kim Nasmyth became scientific director.
In 2006, two institutes of the Austrian Academy of Sciences were opened in the vicinity of the IMP: the Institute of Molecular Biotechnology and the Gregor Mendel Institute (GMI). The three institutes cooperate closely by maintaining shared facilities. In the same year, Barry Dickson became the IMP's scientific director.
Since 2013, Jan-Michael Peters is scientific director of the IMP. In late 2016, the IMP moved into its new building.
Scientists at the IMP publish 60 to 90 papers in international peer-review journals per year: between 1985 and 2017, more than 2,000 research papers were published. 93 patents were filed based on discoveries made at the institute since 1985. IMP faculty was awarded 13 ERC Grants since the establishment of this grant scheme in 2007. Four IMP faculty members received Wittgenstein Awards since 1996.Angelika Amon, master student/PhD student, 1989-1993
Hartmut Beug, senior scientist 1988-2010
Adrian Bird, senior scientist 1987-1990
Max Birnstiel, managing director 1989-1996
Barry Dickson, group leader 1998-2002; managing director 2006-2012
Michael Glotzer, group leader 1997-2005
Konrad Hochedlinger, master student 1998/1999
Thomas Jenuwein, group leader/senior scientist 1993-2008
Kim Nasmyth, senior scientist/managing director 1989-2003
Giulio Superti-Furga, PhD student 1988-1990
Frank Uhlmann, postdoc 1997-2000
Erwin Wagner, senior scientist/deputy director 1988-2008
Martin Zenke, group leader 1988-1995
The "VBC PhD Programme" is an international PhD training program carried out jointly by the four Vienna Biocenter research institutes (IMP, IMBA, GMI and MFPL). Acceptance into the program is competitive and based on a formal selection procedure. There are two selections each year, deadlines are April 30 and November 15. Participation in the program is a condition for doing a PhD at the IMP.
The current IMP building at Campus-Vienna-Biocenter 1 was opened in 2017. It comprises 15,000 square meters of gross floor space and 8,000 square meters of net area, spread over eight levels.
The building contains 3,000 square meters for laboratories and 2,000 square meters for offices; its lecture hall seats up to 280 people. The buildings has six seminar rooms and technical facilities. Some facilities such as cafeteria, but also scientific services, are open to staff from other Vienna Biocenter entities and the IMP building is connected to the neighboring Institute of Molecular Biotechnology building through a bridge.
Several features of the building refer to biological research: the facade features stripes should resemble DNA bands as seen in gel electrophoresis; the central elevator's glass covers are coated with dichroic foils which are also used in filters for light microscopy. The project costs of 52 million Euros were born by the IMP's main sponsor Boehringer Ingelheim.
The following in-house facilities, maintained in cooperation with IMBA, provide support and scientific services to the scientists at IMP:Bioinformatics
Molecular biology service
Mass spectrometry and protein chemistry
Max Perutz Library
Other facilities include the workshop, a graphics department or grant management.
The four research institutes of the Vienna Biocenter maintain a number of shared services jointly called "VBC Core Facilities". The services offered are available to all VBC scientists including IMP staff and are the following:Advanced microscopy
Bioinformatics and scientific computing
Next generation sequencing
Vienna Drosophila Resource Center
Child care facility
In order to maintain a high standard of research, the IMP employs a process of continuous review and feedback. The Scientific Advisory Board (SAB), consisting of distinguished scientists, meets once a year and discusses the quality, significance, and main focus of research conducted at the IMP. The SAB is chaired by Leslie Vosshall of Rockefeller University. Its other members are Angelika Amon (Massachusetts Institute of Technology); Hans Clevers (Hubrecht Institute); Michael Hausser (University College London); Norbert Kraut (Boehringer Ingelheim); Dan Littman (New York University Langone Medical Center); Ruslan Medzhitov (Yale School of Medicine/HHMI); Tom Rapoport (Harvard Medical School); Dirk Schübeler (Friedrich Miescher Institute).
The operating budget of the IMP is provided largely by Boehringer Ingelheim. Support comes from grants awarded to individual scientists and projects by national and international funding agencies such as the Austrian Science Fund (FWF), Austrian Industrial Research Promotion Fund (FFG), the Vienna Science and Technology Fund (WWTF), Zentrum für Innovation und Technologie (ZIT), the City of Vienna, the Austrian federal government, the Human Frontier Science Program (HFSP), and the European Union (EU).